Nativis Research Partner to Present at COGNO Conference in Australia

Nativis CEO to Present at Life Science Innovation Northwest 2017

Nativis, Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced Chris Rivera, Nativis President and CEO will present at Life Science Innovation Northwest (LSIW), North America’s largest, fully-integrated life science exposition May 23-24 at Seattle’s Washington State Convention Center.

Rivera’s LSINW presentation at 3:40 pm on May 23, will focus on the growth and advances made over the past seventeen months since becoming President, CEO and Chairman of Nativis with the Nativis Voyager system, a non-invasive investigational device that delivers ultra-low radio frequency energy (ulRFE™) profiles to the brain. The ulRFE profiles are derived from changes in molecular electrostatic surface potential. The Voyager™ system is being studied in a first-in-human study to assess the safety and feasibility of treatment for recurrent glioblastoma multiforme. Additional information will include recent major scientific papers published by Nativis researchers outlining advances in the work in rGBM and partnering progress.

Further information will be shared about the recently released abstract published online for the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2017, in Chicago, IL. The abstract, entitled “A Feasibility Study of the Nativis Voyager™ System in Patients with Recurrent Glioblastoma Multiforme (GBM): Interim results of first-in-human study,” highlights the results of the first part of a 2-stage study. Abstracts are available to the public at

“We are looking forward to presenting at LSINW and letting the attendees know about the advances made over the past year and a half as we continue to pioneer our novel ulRFE technology,” commented Rivera. “I’ll also be covering the results of our funding efforts, recent partnership with Teijin Pharma, and advances in other areas of our business.  I hope everyone will join me in attending LSINW this year.”

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive investigational device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.  Nativis Voyager® ulRFE™ System for rGBM is an investigational medical device. Limited by Federal (or United States) law to investigational use only.

Investor Relations Contact:

Lee Roth / Tram Bui /

646-536-7012 / 7035

Media Relations Contact:

Aaron Blank / Amber Benson /


Back to News